BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22182920)

  • 1. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
    Weisberg E; Azab AK; Manley PW; Kung AL; Christie AL; Bronson R; Ghobrial IM; Griffin JD
    Leukemia; 2012 May; 26(5):985-90. PubMed ID: 22182920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
    Dillmann F; Veldwijk MR; Laufs S; Sperandio M; Calandra G; Wenz F; Zeller J; Fruehauf S
    Leuk Lymphoma; 2009 Oct; 50(10):1676-86. PubMed ID: 19657955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
    Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
    Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
    Tabe Y; Jin L; Iwabuchi K; Wang RY; Ichikawa N; Miida T; Cortes J; Andreeff M; Konopleva M
    Leukemia; 2012 May; 26(5):883-92. PubMed ID: 22005789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
    Agarwal A; Fleischman AG; Petersen CL; MacKenzie R; Luty S; Loriaux M; Druker BJ; Woltjer RL; Deininger MW
    Blood; 2012 Sep; 120(13):2658-68. PubMed ID: 22889761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
    Saglio G; Fava C
    Leuk Lymphoma; 2009 Oct; 50(10):1564-5. PubMed ID: 19757319
    [No Abstract]   [Full Text] [Related]  

  • 7. Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
    Liu P; Ma D; Yu Z; Zhe N; Ren M; Wang P; Yu M; Huang J; Fang Q; Wang J
    Biomed Pharmacother; 2017 Jul; 91():21-30. PubMed ID: 28445830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
    Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
    Jin L; Tabe Y; Konoplev S; Xu Y; Leysath CE; Lu H; Kimura S; Ohsaka A; Rios MB; Calvert L; Kantarjian H; Andreeff M; Konopleva M
    Mol Cancer Ther; 2008 Jan; 7(1):48-58. PubMed ID: 18202009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
    Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
    PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
    Weisberg E; Wright RD; McMillin DW; Mitsiades C; Ray A; Barrett R; Adamia S; Stone R; Galinsky I; Kung AL; Griffin JD
    Mol Cancer Ther; 2008 May; 7(5):1121-9. PubMed ID: 18445657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
    Herrmann O; Kuepper MK; Bütow M; Costa IG; Appelmann I; Beier F; Luedde T; Braunschweig T; Koschmieder S; Brümmendorf TH; Schemionek M
    BMC Cancer; 2019 Jul; 19(1):658. PubMed ID: 31272418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.
    Vianello F; Villanova F; Tisato V; Lymperi S; Ho KK; Gomes AR; Marin D; Bonnet D; Apperley J; Lam EW; Dazzi F
    Haematologica; 2010 Jul; 95(7):1081-9. PubMed ID: 20179085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
    Herrmann AB; Müller ML; Orth MF; Müller JP; Zernecke A; Hochhaus A; Ernst T; Butt E; Frietsch JJ
    J Cell Mol Med; 2020 Mar; 24(5):2942-2955. PubMed ID: 31957290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
    Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
    Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.
    Jacobi A; Thieme S; Lehmann R; Ugarte F; Malech HL; Koch S; Thiede C; Müller K; Bornhäuser M; Ryser M; Brenner S
    Exp Hematol; 2010 Mar; 38(3):180-90. PubMed ID: 20035824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
    Mayerhofer M; Gleixner KV; Mayerhofer J; Hoermann G; Jaeger E; Aichberger KJ; Ott RG; Greish K; Nakamura H; Derdak S; Samorapoompichit P; Pickl WF; Sexl V; Esterbauer H; Schwarzinger I; Sillaber C; Maeda H; Valent P
    Blood; 2008 Feb; 111(4):2200-10. PubMed ID: 18024796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.